Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Status:
Terminated
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
This is a phase 1, interventional single arm, open label, treatment study designed to
evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6
(IL-6) inhibition in participants with relapsed disease post-allogeneic transplant.